Clinical management of COVID-19 patients: living guidance, 25 January 2021

Published by World Health Organization (WHO) on Mar 16, 2021

Disclaimer

This document is the update of an interim guidance originally published under the title “Clinical management of COVID-19: interim guidance, 27 May 2020".

WHO continues to monitor the situation closely for any changes that may affect this interim guidance. Should any factors change, WHO will issue a further update. Otherwise, this interim guidance document will expire 2 years after the date of publication.
© World Health Organization 2021. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence. WHO reference number: WHO/2019-nCoV/clinical/2021.1

Sponsors

Contact

Abstract

Language

en

PICOS

PICO 12.1

Population
Patients treated at home with confirmed or suspected COVID-19 disease
Intervention
SpO2 < 92% (Pulse oximetry use at home)
Comparator
SpO2 ≥ 92% (Pulse oximetry use at home)
Outcomes

PICO 13.1

Population
Patients hospitalized with severe COVID-19 infection
Intervention
Awake prone positioning + usual care
Comparator
Usual care
Outcomes

PICO 16.1

Population
Hospitalized patients without an indication for therapeutic anticoagulation
Intervention
Anticoagulation at therapeutic or intermediate intensity
Comparator
Anticoagulation at prophylactic intensity
Outcomes

PICO 16.2

Population
Patients with COVID-19 and ARDS or viral pneumonia who are critically ill in ICU, with or without invasive ventilation. Populations of children (defined <18 years) and adult patients (≥18 years)
Intervention
Existing validated care bundles*, chosen locally by the hospital or ICU, adapted to local circumstances, and felt to be appropriate for patients with COVID-19 as specified above. *A care bundle is defined as three or more evidence informed practices delivered together and consistently to improve care.
Comparator
Not using existing care bundles
Outcomes